Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COEPNASDAQ:FTLFNASDAQ:RAPTNASDAQ:SLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOEPCoeptis Therapeutics$9.19-11.7%$9.53$2.31▼$13.70$32.29M-0.66117,813 shs96,749 shsFTLFFitLife Brands$14.44-1.0%$13.53$9.83▼$17.75$135.61M0.918,286 shs17,848 shsRAPTRAPT Therapeutics$0.98-20.7%$0.98$0.71▼$4.60$129.09M-0.041.29 million shs3.46 million shsSLNSilence Therapeutics$5.00-1.2%$3.49$1.97▼$22.47$149.65M1.2300,986 shs139,376 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOEPCoeptis Therapeutics-11.72%-4.87%+19.35%-18.53%+59.71%FTLFFitLife Brands-0.96%+3.14%+0.98%-4.33%-3.73%RAPTRAPT Therapeutics-20.67%+1.30%+11.06%-16.60%-76.66%SLNSilence Therapeutics-1.19%-2.72%+48.81%+4.82%-77.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOEPCoeptis Therapeutics0.5529 of 5 stars0.03.00.00.02.71.70.0FTLFFitLife Brands4.4844 of 5 stars3.75.00.00.02.53.33.1RAPTRAPT Therapeutics4.2902 of 5 stars3.24.00.04.22.61.71.3SLNSilence Therapeutics3.6952 of 5 stars4.44.00.00.03.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOEPCoeptis Therapeutics 2.00HoldN/AN/AFTLFFitLife Brands 3.33Buy$20.5041.97% UpsideRAPTRAPT Therapeutics 2.33Hold$3.00207.44% UpsideSLNSilence Therapeutics 2.71Moderate Buy$33.83576.67% UpsideCurrent Analyst Ratings BreakdownLatest COEP, SLN, FTLF, and RAPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.005/22/2025RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$6.005/9/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$4.00 ➝ $3.005/9/2025SLNSilence TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.005/9/2025SLNSilence TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $35.003/17/2025FTLFFitLife BrandsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.003/10/2025RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/7/2025SLNSilence TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.003/5/2025SLNSilence TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$49.00 ➝ $45.003/4/2025SLNSilence TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$67.00 ➝ $25.003/4/2025SLNSilence TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$6.00 ➝ $4.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOEPCoeptis Therapeutics$62.87K513.63N/AN/A$0.48 per share19.15FTLFFitLife Brands$63.86M2.12$0.76 per share19.05$3.04 per share4.75RAPTRAPT Therapeutics$1.53M84.37N/AN/A$4.27 per share0.23SLNSilence Therapeutics$27.70M5.40N/AN/A$0.71 per share7.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOEPCoeptis Therapeutics-$21.27M-$5.80N/A∞N/AN/A-1,094.50%-219.97%N/AFTLFFitLife Brands$5.30M$0.8417.0913.13N/A13.38%28.03%15.13%N/ARAPTRAPT Therapeutics-$116.80M-$2.40N/AN/AN/AN/A-89.10%-76.13%8/14/2025 (Estimated)SLNSilence Therapeutics-$53.82M-$1.50N/AN/AN/A-342.00%-62.81%-33.89%N/ALatest COEP, SLN, FTLF, and RAPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025FTLFFitLife Brands$0.24$0.20-$0.04$0.20N/AN/A5/14/2025Q1 2025COEPCoeptis TherapeuticsN/A-$1.11N/A-$1.11N/AN/A5/8/2025Q1 2025RAPTRAPT Therapeutics-$0.31-$0.08+$0.23-$0.08N/AN/A5/8/2025Q1 2025SLNSilence Therapeutics-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million3/27/2025Q4 2024FTLFFitLife Brands$0.22$0.21-$0.01N/AN/AN/A3/6/2025Q4 2024RAPTRAPT Therapeutics-$0.45-$1.14-$0.69-$1.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOEPCoeptis TherapeuticsN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ASLNSilence TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOEPCoeptis Therapeutics0.030.400.40FTLFFitLife Brands0.281.500.64RAPTRAPT TherapeuticsN/A9.909.90SLNSilence TherapeuticsN/A9.319.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOEPCoeptis Therapeutics13.88%FTLFFitLife Brands2.32%RAPTRAPT Therapeutics99.09%SLNSilence Therapeutics98.73%Insider OwnershipCompanyInsider OwnershipCOEPCoeptis Therapeutics24.25%FTLFFitLife Brands61.30%RAPTRAPT Therapeutics2.36%SLNSilence Therapeutics2.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOEPCoeptis Therapeutics23.51 million2.46 millionNot OptionableFTLFFitLife Brands209.39 million3.56 millionNot OptionableRAPTRAPT Therapeutics80132.29 million32.65 millionOptionableSLNSilence Therapeutics10029.93 millionN/ANot OptionableCOEP, SLN, FTLF, and RAPT HeadlinesRecent News About These CompaniesSilence Therapeutics plc (NASDAQ:SLN) Shares Bought by Woodline Partners LPMay 27 at 4:38 AM | marketbeat.comPoint72 Asset Management L.P. Has $4.36 Million Stock Position in Silence Therapeutics plc (NASDAQ:SLN)May 22, 2025 | marketbeat.comWall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to TradeMay 21, 2025 | zacks.comSilence Therapeutics plc (NASDAQ:SLN) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Takes Position in Silence Therapeutics plc (NASDAQ:SLN)May 14, 2025 | marketbeat.comWhat is William Blair's Forecast for SLN FY2027 Earnings?May 14, 2025 | marketbeat.comSilence Therapeutics (NASDAQ:SLN) Price Target Lowered to $35.00 at Chardan CapitalMay 11, 2025 | marketbeat.comSilence Therapeutics (SLN) Projected to Post Quarterly Earnings on ThursdayMay 10, 2025 | marketbeat.comSilence Therapeutics plc GAAP EPS of -C$0.20May 8, 2025 | seekingalpha.comCantor Fitzgerald L. P. Buys 205,534 Shares of Silence Therapeutics plc (NASDAQ:SLN)May 7, 2025 | marketbeat.comSilence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | finanznachrichten.deSilence Therapeutics Welcomes Tim McInerney to Board of DirectorsMay 6, 2025 | businesswire.comSilence Therapeutics plc (NASDAQ:SLN) Stock Holdings Increased by Nantahala Capital Management LLCApril 30, 2025 | marketbeat.comBoothbay Fund Management LLC Has $2.42 Million Position in Silence Therapeutics plc (NASDAQ:SLN)April 30, 2025 | marketbeat.comMarshall Wace LLP Purchases 320,472 Shares of Silence Therapeutics plc (NASDAQ:SLN)April 28, 2025 | marketbeat.comSilence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are BuyingApril 23, 2025 | insidermonkey.comSilence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare ConferenceMarch 5, 2025 | businesswire.comSilence Therapeutics (SLN) Upgraded to Buy: Here's What You Should KnowMarch 4, 2025 | zacks.comSilence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 1, 2025 | uk.finance.yahoo.comSilence Therapeutics plc (SLN) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comSilence Quiets Phase III Pace for Lipoprotein Drug, Seeks PartnerFebruary 28, 2025 | biospace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOEP, SLN, FTLF, and RAPT Company DescriptionsCoeptis Therapeutics NASDAQ:COEP$9.19 -1.22 (-11.72%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$9.60 +0.41 (+4.41%) As of 05/27/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.FitLife Brands NASDAQ:FTLF$14.42 -0.17 (-1.13%) As of 05/27/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.RAPT Therapeutics NASDAQ:RAPT$0.98 -0.25 (-20.67%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$0.98 +0.00 (+0.43%) As of 05/27/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanySilence Therapeutics NASDAQ:SLN$5.00 -0.06 (-1.19%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$5.02 +0.02 (+0.40%) As of 05/27/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.